Compare Quest Diagnostics Inc (DGX) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Nutrien Ltd — how do they compare? Quest Diagnostics Inc trades at $230.89 (market cap $25.48B), while Nutrien Ltd trades at $67.2 (market cap $33.31B). The key difference: Nutrien Ltd is the larger of the two by market cap, and Nutrien Ltd pays the higher dividend (3.15%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Nutrien Ltd for 59 Days on average.
| DGX | NTR | |
|---|---|---|
Market Cap | $25.48B | $33.31B |
Volume | 941,866 | 1,330,729 |
Sector | Health | Basic Materials |
52-Week High | $247.45 | $83.94 |
52-Week Low | $173.49 | $53.64 |
Typical Hold Time | 56 Days | 59 Days |
Enterprise Value | $31.23B | $45.11B |
Dividend Yield | 1.49% | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Nutrien (NTR) trades at $68.29, down 2.4% today, with a bearish technical signal and mixed earnings history. The stock shows moderate valuation metrics with P/E of 14.14 and P/S of 1.2, while profitability metrics include 8.44% net margin and 9.34% ROE. Recent news highlights industry headwinds from potential Belarus potash imports and an upcoming Investor Day in November 2026.
The outlook remains cautiously optimistic with 60.6% analyst buy ratings and a $76.14 consensus target, though risks include fertilizer price volatility and competitive pressures. Cash flow trends show consistent operational strength but negative net flows in recent years, requiring careful monitoring of debt levels and agricultural market cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
